Table 3.
No imputation (P) | Method 1 (P) | Method 2 (P) | Method 3 (P) | Method 4 (P) | Overall statistically significant | |
---|---|---|---|---|---|---|
GM3/17 | 0·99 n.s. | 0·8 n.s. | 0·4 n.s. | 0·6 n.s. | 0·7 n.s. | 0/5 |
GM17/17 | 0·04 1 | 0·01 1 | 0·05 2 | 0·08 2 | 0·08 2 | 4/5 |
GM23−/+ | 0·009 1 | 0·004 1 | 0·01 1 | 0·04 1 | 0·04 1 | 5/5 |
GM23+/+ | 0·01 1 | 0·009 1 | 0·01 1 | 0·06 2 | 0·05 2 | 4/5 |
KIR2DS2 | 0·06 2 | 0·01 1 | 0·01 1 | 0·02 1 | 0·02 1 | 5/5 |
KIR2DS5 | 0·02 1 | 0·01 1 | 0·02 1 | 0·06 2 | 0·05 2 | 5/5 |
HLA‐C2 | 0·07 2 | 0·02 1 | 0·02 1 | 0·03 1 | 0·03 1 | 5/5 |
HLA‐Bw4T | 0·05 2 | 0·03 1 | 0·05 2 | 0·05 2 | 0·07 2 | 5/5 |
Haplotype AA | 0·47 n.s. | 0·45 n.s. | 0·20 n.s. | 0·16 n.s. | 0·18 n.s. | 0/5 |
We report the following degree of evidence against the null hypothesis: 1statistical significance (P < 0·05); 2weak statistical significance (P < 0·10); n.s., not significant. TThreonine.